primed for clinical success.
Our AVATAR proprietary metabolic reprogramming technology delivers potent and persistent cells.
AVATAR TECHNOLOGY
The Most Potent and Persistent Cell Therapies
Proprietary incubation technology mimics in-vivo tumor microenvironments, replicating key stressors like hypoxia and pressure
Optimized manufacturing conditions for CAR T, TIL, TCR T and Treg cells
Enhanced Cell Fitness, Even for Solid Tumors
AVATAR-trained cells retain metabolic fitness and are better suited for tumor microenvironments
AVATAR-Expanded CAR T cells are 70% More potent in TME Conditions
80
60
40
20
0
Conventional
CAR T cells
AVATAR
CAR T cells
% Cytotoxicity
Poor cytotoxicity is observed when cells are not conditioned to the challenging environment (left bar). Cells grown under more physiological conditions (right bar) show increased potency under TME conditions.
70% Increased
Killing in TME
Conditions
Cell Fitness in
the Tumor
microenvironment
-
Hypoxia, high interstitial pressure, and immunosuppressive proteins create a hostile microenvironment pH for therapeutic cells
-
Conventional incubation systems fail to prepare cells for this reality—resulting in early exhaustion, poor in vivo performance, and limited clinical success
-
Cell therapies produced in small-scale quantities face the problem of emulating those conditions in separate GMP manufacturing systems
Seamless Transfer from Discovery to Manufacturing
Designed specifically to maintain & expand primary human cells
Same in vivo environment across the instrument family
Foundry
HOW IT WORKS
AVATAR systems activate mechano- and oxygen-sensing pathways that improve:
-
Glucose uptake and oxidative metabolism
-
Stress resistance in hypoxic conditions
-
Transduction vector access during pressurization
Cells become “TME-conditioned” and carry those traits into in vivo settings. The result? Cell therapy products that are better equipped to overcome immune suppression, persist longer, and deliver superior therapeutic outcomes compared to cells expanded under traditional conditions.
Proven Performance Under Pressure
Explore how AVATAR technology enhances T cell potency, persistence, and efficiency by recreating the tumor micro-environment in manufacturing.
Double the Killing Power of CAR T cells
Hyperbaric pressure and precise oxygen regulation provide optimal manufacturing conditions for producing potent & persistent therapeutic cells. The data demonstrate a significant boost to CAR T cell potency.
Conventional CAR T cells
AVATAR
CAR T cells
Persistent Killing Over Repeated Tumor Challenges
CAR T cells manufactured under reduced oxygen and enhanced pressure exhibit persistent cytotoxic activity over repeated tumor challenges without exhaustion.
Conventional CAR T cells
AVATAR CAR T cells
Challenge 1
Challenge 2
Challenge 3
Challenge 4
Challenge 5
2X Enhanced Metabolism to Power T cell Potency
GLUT1, the primary glucose transporter in T cells, is associated with improved potency in solid tumor microenvironments and is significantly upregulated in CAR T cells expanded with AVATAR technology.
Conventional CAR T cells
AVATAR
CAR T cells
2X Increased Rapid Cell Expansion for Clinical-Scale
Growing cells under an optimized environment increases the expansion of challenging patient-derived cells, as shown by the increased CAR T cell expansion. In this setting, ambient oxygen concentrations are maintained while hyperbaric pressure is increased.
Conventional CAR T cells
AVATAR
CAR T cells
30% Increased Transduction and Lower Vector Cost
Viral transduction under pressurized culture conditions increases efficiency, lowering vector cost and enhancing potency. The data demonstrates how the AVATAR platform can optimize CAR T transduction efficiency.
Conventional CAR T cells
AVATAR
CAR T cells
Sustained Tumor Killing, Even at Low E:T Ratios
TCR T cells expanded with AVATAR technology maintain strong cytotoxic function at low effector-to-target ratios that mirror the tumor microenvironment where limiting numbers of T cells must persistently kill tumor cells without exhaustion.
Effector : Target Ratio
Conventional TCR T cells
AVATAR TCR T cells
1:10
1:30
1:50